Gyno-Daktarin (Miconazole Nitrate)

Gyno‑Daktarin is indicated for the treatment of fungal infections of the female genital tract.

• Vulvovaginal candidiasis caused by Candida species.
• Acute yeast infections presenting with itching, burning, and discharge.
• Maintenance therapy to reduce recurrence after successful initial treatment.
• Adjunctive use with other topical agents when mixed infections are suspected.
• Off‑label use for other superficial fungal infections of the vulva as directed by a healthcare professional.

Local application of miconazole nitrate may cause a range of side effects, most of which are mild and resolve without intervention.

Common

• Mild vaginal irritation or burning sensation.
• Itching or redness of the vulvar skin.
• Unpleasant taste or odor from the product.
• Vaginal discharge that is watery or slightly cloudy.
• Minor spotting or spotting after application.
• Dryness of the vaginal mucosa.
• Headache (rare).

Serious

• Severe allergic reaction with swelling of the face, lips, or tongue.
• Persistent or worsening vaginal irritation that does not improve after several days.
• Signs of systemic infection such as fever.

Before using Gyno‑Daktarin, certain precautions should be considered to ensure safe and effective treatment.

• Confirm diagnosis of a fungal infection; other conditions may mimic symptoms.
• Avoid use if you have a known hypersensitivity to miconazole or any imidazole antifungal.
• Do not use the product during menstruation unless directed by a healthcare provider.
• If you are pregnant, breastfeeding, or planning pregnancy, discuss use with a clinician.
• Discontinue use and seek medical advice if severe irritation or allergic signs develop.
• Store the medication at room temperature, away from moisture and direct sunlight.

Miconazole nitrate can interact with other medicines or substances; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Concurrent use of systemic azole antifungals (e.g., fluconazole, itraconazole) that may increase systemic exposure.
• Use with estrogen‑containing vaginal products that could alter absorption.
• Application of other topical irritants (e.g., douches, scented soaps) in the same area.

Use with caution

• Anticoagulant therapy (e.g., warfarin) as miconazole may affect clotting parameters.
• Hormonal contraceptives, although systemic effects are minimal, monitor for any changes.
• Use with other vaginal medications; spacing applications can reduce potential for irritation.